These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 7718484)

  • 1. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf.
    Topol LZ; Marx M; Calothy G; Blair DG
    Cell Growth Differ; 1995 Jan; 6(1):27-38. PubMed ID: 7718484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the mitogen-activated protein kinase cascade in response to the temperature inducible expression of v-mos kinase.
    Topol LZ; Blair DG
    Cell Growth Differ; 1995 Sep; 6(9):1119-27. PubMed ID: 8519689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCH 51344 inhibits ras transformation by a novel mechanism.
    Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
    Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of insulin on the activation of the Raf/Mos-dependent MAP kinase cascade in vitellogenic versus postvitellogenic Xenopus oocytes.
    Chesnel F; Bonnec G; Tardivel A; Boujard D
    Dev Biol; 1997 Aug; 188(1):122-33. PubMed ID: 9245517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for involvement of the protein kinase C pathway in the activation of p37v-mos protein kinase.
    al-Bagdadi F; Singh B; Arlinghaus RB
    Oncogene; 1990 Aug; 5(8):1251-7. PubMed ID: 2168030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum.
    Kolch W; Heidecker G; Troppmair J; Yanagihara K; Bassin RH; Rapp UR
    Oncogene; 1993 Feb; 8(2):361-70. PubMed ID: 8426742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delay in serum stimulation of Erk activity caused by oncogenic transformation.
    Greulich H; Reichman C; Hanafusa H
    Oncogene; 1996 Apr; 12(8):1689-95. PubMed ID: 8622889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple pathways for activation of MAP kinases.
    Mitra G; Weber M; Stacey D
    Cell Mol Biol Res; 1993; 39(5):517-23. PubMed ID: 8173594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for Ras in v-Crk transformation.
    Greulich H; Hanafusa H
    Cell Growth Differ; 1996 Nov; 7(11):1443-51. PubMed ID: 8930393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dominant suppressive mutation in a cellular gene restores the nontransformed phenotype to v-fms-transformed mink cells.
    Kato J; Sherr CJ
    Oncogene; 1991 May; 6(5):687-93. PubMed ID: 2052353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. v-raf confers CSF-1 independent growth to a macrophage cell line and leads to immediate early gene expression without MAP-kinase activation.
    Büscher D; Dello Sbarba P; Hipskind RA; Rapp UR; Stanley ER; Baccarini M
    Oncogene; 1993 Dec; 8(12):3323-32. PubMed ID: 8247534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter.
    Kukushkin AN; Abramova MV; Svetlikova SB; Darieva ZA; Pospelova TV; Pospelov VA
    Oncogene; 2002 Jan; 21(5):719-30. PubMed ID: 11850800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single Glu(62)-to-Lys(62) mutation in the Mos residues of the R7Delta447Gag-tMos protein causes the mutant virus to induce brain lesions.
    Yuen PH; Ryan EA; Devroe E; Wong PK
    Oncogene; 2001 Feb; 20(6):692-703. PubMed ID: 11314003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor.
    York RD; Yao H; Dillon T; Ellig CL; Eckert SP; McCleskey EW; Stork PJ
    Nature; 1998 Apr; 392(6676):622-6. PubMed ID: 9560161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of a new class of 'flat' revertants from ras-transformed NIH3T3 cells using cis-4-hydroxy-L-proline.
    Yanagihara K; Ciardiello F; Talbot N; McGeady ML; Cooper H; Benade L; Salomon DS; Bassin RH
    Oncogene; 1990 Aug; 5(8):1179-86. PubMed ID: 2202950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repression of mitogen-activated protein kinases ERK1/ERK2 activity by a protein tyrosine phosphatase in rat fibroblasts transformed by upstream oncoproteins.
    Gopalbhai K; Meloche S
    J Cell Physiol; 1998 Jan; 174(1):35-47. PubMed ID: 9397154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutively active mitogen-activated protein kinase kinase 1 (MAPKK1) and MAPKK2 mediate similar transcriptional and morphological responses.
    Mansour SJ; Candia JM; Gloor KK; Ahn NG
    Cell Growth Differ; 1996 Feb; 7(2):243-50. PubMed ID: 8822208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of v-mos Ser 47 by the mitotic form of p34cdc2.
    Bai WL; Singh B; Karshin WL; Shonk RA; Arlinghaus RB
    Oncogene; 1991 Oct; 6(10):1715-23. PubMed ID: 1833715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitogenesis by v-Src: fluctuations throughout G1 of classical immediate early AP-1 and mitogen-activated protein kinase responses that parallel the need for the oncoprotein.
    Wyke AW; Frame MC; Gillespie DA; Chudleigh A; Wyke JA
    Cell Growth Differ; 1995 Oct; 6(10):1225-34. PubMed ID: 8845299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.